Takeda Pharmaceuticals U.S.A., Inc.
$199.9M 172,058 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
BioNTech SE
BioNTech SE reported $204,815,512.05 across General Payments, Research, and Ownership to 179 physicians and teaching hospitals across 4,756 transactions.
- $204.8M Top 1% payer
- All-tracks total
- 4,756 Top quartile volume
- Transactions
- 179 Above-median reach
- Recipients
- −$187.3M
- General Payments vs PY2023
BioNTech SE reported $204,815,512.05 across all CMS Open Payments tracks (General + Research + Ownership) to 179 physicians and teaching hospitals in Program Year 2024 - ranking #14 of 1,925 reporting manufacturers (1.5% of the all-tracks industry total); General Payments alone were $180,574,537.46, averaging $1.1M per recipient.
How BioNTech SE's $204.8M all-tracks total breaks down
BioNTech SE's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
55/100
Total payments
A
100/100
Transaction volume
F
45/100
Physician reach
F
11/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer biontech-se BioNTech SE
$204.8M · #14/1,925 · 1.5% industry · PY2024
- TOT $204.8M
- RANK #14
- SHARE 1.5%
- TXN 4,756
- RCP 179
- CAT 5
- GEN $180.6M
- ΔGEN −$187.3M
- TOP1 99.8%
- PY 2024
Volume peers
Nearest volume peer: Takeda Pharmaceuticals U.S.A., Inc. ($199.9M)
BioNTech SE sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
BioNTech SE's CMS-reported General Payments decreased by $187.3M (−50.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BIONTECH SEPY2023: BIONTECH SEPY2024: BioNTech SE. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $367,885,404.76
- PY2024
- $180,574,537.46
What the Data Shows for BioNTech SE
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For BioNTech SE, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 5 general-payment categories charted below, "Royalty or License" is the largest at $180.3M across 16 transactions, 99.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Royalty or License" leads BioNTech SE's 5-category general-payment breakdown at $180.3M, 99.8% of the reported total.
BioNTech SE reports 5 general-payment categories - the top three are Royalty or License (99.8%), Consulting Fee (0.1%), and Travel and Lodging (0.0%). The remaining 2 categories make up 0.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How BioNTech SE divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $180.3M | 16 | 99.8% |
| Consulting Fee | $172.1K | 47 | 0.1% |
| Travel and Lodging | $83.0K | 38 | 0.0% |
| Compensation for Services Other Than Consulting | $19.9K | 11 | 0.0% |
| Food and Beverage | $4.5K | 67 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $180,404,003.93 (99.9%) of $180,574,537.46 in this company's General Payments records across 54 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for BioNTech SE
The five named recipients with the highest reported General Payments from this company
- 1
Hospital Of The Univ Of Penna
$180,204,077.24 across 23 reported transactions
- 2
University Of Washington Med Ctr
$134,500.00 across 2 reported transactions
- 3
John V. Heymach
$25,615.29 across 10 reported transactions
- 4
Bhavana Pothuri
$23,357.19 across 11 reported transactions
- 5
Philip Philip
$16,454.21 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
BioNTech SE's spend rank (#14 of 1,925, top 1% by spend) and concentration rank (#134 of 1,838, top 7% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Jcbd, LLC : $65.3K total payments, HHI 10000
- Diagnostic Green GmbH : $36.0K total payments, HHI 10000
- Pixee Medical Inc. : $601.00 total payments, HHI 10000
- InSightec,LTD : $865.8K total payments, HHI 9998
- Edge Endo LLC : $91.1M total payments, HHI 9988
- Ikon Spine LLC : $120.5K total payments, HHI 9985
- BioNTech SE (this company) : $180.6M total payments, HHI 9959
- Caption Health, Inc. : $7.5K total payments, HHI 9935
- Aptis Medical, LLC : $1.2M total payments, HHI 9916
- Global Kinetics USA Corporation : $52.4K total payments, HHI 9914
- BrioHealth Solutions, Inc. : $392.9K total payments, HHI 9908
- Synaptic Medical Corporation : $89.1K total payments, HHI 9906
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as BioNTech SE's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about BioNTech SE.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with BioNTech SE.
Showing 6 of 1,924 companies with CMS-reported payment data.
Medtronic, Inc.
$189.9M 342,681 recipients
Compare payment profiles
GlaxoSmithKline, LLC.
$242.1M 341,439 recipients
Compare payment profiles
E.R. Squibb & Sons, L.L.C.
$251.5M 236,558 recipients
Compare payment profiles
Boehringer Ingelheim Pharmaceuticals, Inc.
$148.9M 216,716 recipients
Compare payment profiles
Stryker Corporation
$141.0M 168,381 recipients
Compare payment profiles
Put this to use
BioNTech SE ranks #14 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See where BioNTech SE sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just BioNTech SE. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.